Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc. reports significant progress in its drug development efforts, driven by strong shareholder support and strategic advancements with the FDA. The company highlights promising results for its ATI-1701 vaccine and ATI-1801 topical treatment, both showing potential in addressing serious infectious diseases.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
